MYNZ | Mainz Biomed B.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3168 - 0.3400
52 Week Range	0.3060 - 4.38
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2,296,557
Average Volume	1,256,782
Shares Outstanding	21,886,576
Market Cap	7,145,967
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2021-11-05

Valuation
Profitability
Growth
Health
P/E Ratio	-0.20
Forward P/E Ratio	N/A
EPS	-1.62
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	65
Country	Germany
Website	MYNZ

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

MYNZ's peers: APDN, CNTG, STIM, PRE, FONR, GTH, OLK, MDXH, NOTV, STRRP, LAB, BDSX, NDRA, SERA, DRIO, BNR, LMDX

*Chart delayed

Analyzing fundamentals for MYNZ we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see MYNZ Fundamentals page.

Watching at MYNZ technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MYNZ Technicals page.